Literature DB >> 10417342

Autocrine regulation of growth stimulation in human epithelial ovarian carcinoma by serine-proteinase-catalysed release of the urinary-type-plasminogen-activator N-terminal fragment.

D A Fishman1, A Kearns, S Larsh, J J Enghild, M S Stack.   

Abstract

Ovarian carcinomas secrete single-chain urinary-type plasminogen activator (scuPA) and expression of uPA is up-regulated relative to normal ovarian epithelium, leading to an enhanced proteolytic capacity which may facilitate invasion. Furthermore, the uPA receptor (uPAR) is present on ovarian carcinoma cells and is occupied in tumour tissues. In the present study, incubation of scuPA with serum-free conditioned medium from ovarian carcinoma cells resulted in release of a 14 kDa polypeptide. N-terminal sequence analysis identified this fragment as the uPA N-terminal fragment (NTF), which contains a growth-factor and a kringle domain. NTF generation was abolished by serine-proteinase inhibitors, but not inhibitors of matrix metalloproteinases, and was not enhanced by the addition of plasminogen or plasmin. To determine whether ovarian carcinoma-cell growth is altered by uPA, the effect of exogenous scuPA or NTF on proliferation was analysed. Both NTF and scuPA induced a dose-dependent increase in proliferation, with maximal stimulation obtained at 10-20 nM. Furthermore, blocking the interaction of endogenous uPA with uPAR using anti-NTF antibodies significantly inhibited proliferation. Together these data indicate that, in addition to enhancing the invasive activity of ovarian carcinoma cells via increased pericellular proteolysis, uPA also acts as a mitogen for ovarian carcinoma cells, suggesting a biochemical mechanism whereby uPA may contribute to ovarian carcinoma progression by modulating both cell invasion and proliferation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10417342      PMCID: PMC1220416     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  22 in total

1.  The two human trypsinogens. Inhibition spectra of the two human trypsins derived from their purified zymogens.

Authors:  C Figarella; G A Negri; O Guy
Journal:  Eur J Biochem       Date:  1975-05-06

2.  Proliferation of a human epidermal tumor cell line stimulated by urokinase.

Authors:  J C Kirchheimer; J Wojta; G Christ; B R Binder
Journal:  FASEB J       Date:  1987-08       Impact factor: 5.191

3.  Activation with plasmin of tow-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin.

Authors:  H R Lijnen; B Van Hoef; D Collen
Journal:  Eur J Biochem       Date:  1987-12-01

Review 4.  The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma.

Authors:  M S Stack; S M Ellerbroek; D A Fishman
Journal:  Int J Oncol       Date:  1998-03       Impact factor: 5.650

5.  Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B.

Authors:  H Kobayashi; H Ohi; M Sugimura; H Shinohara; T Fujii; T Terao
Journal:  Cancer Res       Date:  1992-07-01       Impact factor: 12.701

6.  An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells.

Authors:  S A Rabbani; J Desjardins; A W Bell; D Banville; A Mazar; J Henkin; D Goltzman
Journal:  Biochem Biophys Res Commun       Date:  1990-12-31       Impact factor: 3.575

7.  The matrix metalloproteinase pump-1 catalyzes formation of low molecular weight (pro)urokinase in cultures of normal human kidney cells.

Authors:  P A Marcotte; I M Kozan; S A Dorwin; J M Ryan
Journal:  J Biol Chem       Date:  1992-07-15       Impact factor: 5.157

8.  Cyst fluid of ovarian cancer patients contains high concentrations of trypsinogen-2.

Authors:  E Koivunen; O Itkonen; H Halila; U H Stenman
Journal:  Cancer Res       Date:  1990-04-15       Impact factor: 12.701

9.  Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells.

Authors:  J C Kirchheimer; J Wojta; G Christ; G Hienert; B R Binder
Journal:  Carcinogenesis       Date:  1988-11       Impact factor: 4.944

10.  Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.

Authors:  S A Rabbani; A P Mazar; S M Bernier; M Haq; I Bolivar; J Henkin; D Goltzman
Journal:  J Biol Chem       Date:  1992-07-15       Impact factor: 5.157

View more
  2 in total

1.  Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding.

Authors:  Daniel Miotto Dupont; Jeppe Buur Madsen; Roland Karl Hartmann; Bertrand Tavitian; Frédéric Ducongé; Jørgen Kjems; Peter André Andreasen
Journal:  RNA       Date:  2010-10-20       Impact factor: 4.942

2.  Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.

Authors:  Zhong Dong; Allen D Saliganan; Hong Meng; Sanaa M Nabha; Aaron L Sabbota; Shijie Sheng; R Daniel Bonfil; Michael L Cher
Journal:  Neoplasia       Date:  2008-05       Impact factor: 5.715

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.